Skip to content

Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder

Subepithelial injection of botulinum toxin A for non-neurogecic overactive bladder - Botulinum toxin injection in non-neurogenic OAB

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001422
Enrollment
45
Registered
2008-10-14
Start date
2008-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-neurogenic overactive bladder

Interventions

After solving Botulinum toxin A 100 units by normal saline 15ml, 30 subepithelial injections avoiding injection into trigone are performed.

Sponsors

National Center for Geriatrics & Gerontology
Lead Sponsor
Tokyo University
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patient has non-neurogenic overactive bladder. 2) Written informd consent is required. 3) One or more times a week of urge urinary incontinence was seen after antichorinergic drugs or antichorinergic drugs could not be continued because of adverse effects.

Exclusion criteria

Exclusion criteria: 1) The patient has apparent neurogenic diseases causing urinary tract symptoms. 2) The patient underwent treatment with botulinum toxin A. 3) The patient underwent the surgery of lower urinary tract within 1 year. 4) Postvoid residual urine is 100ml or greater. 5) The patient has apparent lower urinary tract obstruction and/or weak detrusor. 6) Average voiding volume are 200ml or greater on frequency-volume chart. 7) The patient has stress urinary incontinence and/or functional urinary incontinence. 8) The patient has active urinary tract infection, malignance and/or bladder stone. 9) The patient is pregnant or breast-feed, or have possibility of such matter within 1 year. 10) The patient is diagnosed as having myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis. 11) The patient has disturbance of swallowing and/or respiration. 12) The patitent has mental and/or cognitive disturbance to conduct the clinical trial. 13) The patient is judged as being unsuitable for the trial by the researcher.

Design outcomes

Primary

MeasureTime frame
Change of the number of urge urinary incontinence 1month after treatment

Secondary

MeasureTime frame
Recurrence of urge urinary incontinence, change of bladder capacity and symptoms after treatment

Countries

Japan

Contacts

Public ContactKikuo Okamura

National Center for Geriatrics & Gerontology Division of Urology, Department of Surgery & Intensive Care

kokamura@ncgg.go.jp0562-46-2311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026